<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – November 10, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”), is pleased to report further progress in the Cannabinoids loaded Exosome Delivery Platform (CLX) research. The researchers at Prof. Offen’s laboratory at the Tel Aviv University, have succeeded to characterize the profile of the micro-RNA content in exosomes. The new analysis will allow more accurate characterization of the exosomes intended for…
...read full article on Newsfile Corp